Cheaper, simpler, and better: Tips for treating seniors with Parkinson disease

Mayo Clinic Proceedings

Volumn 86, Issue 12, 2011, Pages 1211-1216

  Ahlskog, J Eric ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; ENTACAPONE; LEVODOPA; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; SELEGILINE;

AKATHISIA; ANXIETY; BEHAVIOR DISORDER; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG TRANSPORT; DYSKINESIA; ELDERLY CARE; GENERAL PRACTITIONER; HALLUCINATION; HUMAN; INSOMNIA; INTERNAL MEDICINE; LIVEDO RETICULARIS; MOTOR DYSFUNCTION; NAUSEA; ORTHOSTATIC HYPOTENSION; PALLIATIVE THERAPY; PANIC; PARKINSON DISEASE; PATIENT CARE; PERIPHERAL EDEMA; PHYSICIAN; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; SEDATION; SIDE EFFECT; SLEEP; UNITED STATES;

EID: 83155173451     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2011.0443     Document Type: Review

References (25)

1. Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:976-982. (Pubitemid 44044779)
2. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361:1268-1278.
3. Ahlskog JE, Uitti RJ. Rasagiline, Parkinson neuroprotection, and delayed- start trials: still no satisfaction? Neurology. 2010;74:1143-1148.
4. Savica R, Rocca WA, Ahlskog JE. When does Parkinson disease start? Arch Neurol. 2010;67:798-801.
5. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004;318:121-134. (Pubitemid 39362633)
6. Ahlskog JE. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease. Mov Disord. 2005;20:271-282. (Pubitemid 40613287)
7. Rascol O, Brooks D, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484-1491. (Pubitemid 30318272)
8. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA. 2000;284:1931-1938.
9. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52:1908-1910. (Pubitemid 29260911)
10. Hassan A, Bower JH, Kumar N, et al. Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies. Parkinsonism Relat Disord. 2011;17:260-264.
11. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448-458. (Pubitemid 36041148)
12. Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov Disord. 2005;20:342-344. (Pubitemid 40613295)
13. Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol. 2006;63:205-209. (Pubitemid 43261731)
14. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord. 1987;2:73-91.
15. Muenter MD, Tyce GM. L-dopa therapy of Parkinson's disease: plasma l-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc. 1971;46:231-239.
16. Muenter MD, Ahlskog JE. Dopa dyskinesias and fluctuations are not related to dopa treatment duration. Ann Neurol. 2000;48:464.
17. Ahlskog JE. Parkinson's disease: does vigorous exercise have a neuroprotective effect in Parkinson's disease? Neurology. 2011;77:288-294.
18. Yeh KC, August TF, Bush DF, et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology. 1989;39:25-38. (Pubitemid 20020578)
19. Ahlskog JE, Muenter MD, McManis PG, Bell GN, Bailey PA. Controlled- release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease. Mayo Clin Proc. 1988;63:876-886.
20. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDEPD study. Ann Neurol. 2010;68:18-27.
21. Hauser RA, Koller WC, Hubble JP, Malapira T, Busenbark K, Olanow CW. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease. Mov Disord. 2000;15:485-489. (Pubitemid 30333220)
22. Boeve BF, Dickson DW, Olson EJ, et al. Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease. Sleep Med. 2007;8:60-64. (Pubitemid 46044137)
23. Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology. 2010;75:494-499.
24. Ahlskog JE. Parkinson's Disease Treatment Guide for Physicians. New York, NY: Oxford University Press; 2009:382.
25. Ahlskog JE. The Parkinson's Disease Treatment Book: Partnering with Your Doctor to Get the Most from Your Medications. New York, NY: Oxford University Press; 2005:532.